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Hepatitis B infection in people living with HIV who initiate 
antiretroviral therapy in Zimbabwe
T. P. Goverwa-Sibanda,1,2 C. Mupanguri,3 C. Timire,3,4,5 A. D. Harries,6,7 S. Ngwenya,2 E. Chikwati,1  
C. Mapfuma,4 F. Mushambi,8 H. Tweya,6,9 M. Ndlovu2,4
Chronic hepatitis B virus (HBV) infection is a ma-jor public health challenge worldwide, with 250 
million people estimated to be hepatitis B surface anti-
gen (HBsAg) positive.1 The highest HBV infection rates 
are in sub-Saharan Africa and the Western Pacific, 
where transmission occurs predominantly in infants 
and children by perinatal and horizontal routes 
through close contact with family members.1,2 The 
outcome of HBV infection is age-dependent, with 95% 
of neonates, 20–30% of children aged 1–5 years and 
5% of adults developing chronic infection.1 There is 
considerable morbidity and mortality associated with 
chronic infection. Approximately 25% of people who 
acquire HBV in infancy or childhood develop cirrhosis 
or liver cancer.3 Various factors increase this risk of 
liver disease, one being advanced immunosuppression 
as a result of HIV co-infection.4–6
There is considerable overlap between HIV infec-
tion and HBV. The global HIV-HBV co-infection preva-
lence is estimated at about 6% among people living 
with HIV (PLHIV), with the greatest burden of dual 
disease being in sub-Saharan Africa.7 This is supported 
by studies from Mozambique, Benin, Ghana and Ethi-
opia showing considerably higher rates of HBV among 
PLHIV.8–11 While HIV hastens the progression of HBV 
to cirrhosis and liver cancer,4–6 HBV, in turn, adversely 
affects the treatment of HIV and is associated with 
poor viral suppression, inadequate CD4 cell recovery 
and continued immune suppression despite antiretro-
viral therapy (ART).12
There are oral antiviral drugs available to treat both 
infections, suppress viral replication, and in the case 
of HBV, reduce hepatic inflammation and prevent pro-
gression to cirrhosis and liver cancer. Lamivudine 
(3TC) and tenofovir (TDF) are respectively the nucleo-
side/nucleotide reverse transcriptase inhibitors (NRTI) 
used to treat both HIV and HBV infections. TDF (in 
the pro drug form of either tenofovir disoproxil fuma-
rate or tenofovir alafenamide) is the recommended 
first-line treatment for HBV because of its high barrier 
to resistance: 3TC is effective, but resistance can de-
velop rapidly, especially with monotherapy.2 None of 
these drugs can eradicate HIV or HBV and long-term 
treatment is therefore required to maintain viral 
suppression.
The National AIDS Programme in Zimbabwe has a 
well-performing HIV care and treatment programme, 
with over one million PLHIV alive and on ART.13 Two 
studies from Zimbabwe collecting blood samples be-
tween 2003 and 2014 in the largely pre-ART era 
showed that 11–17% of PLHIV had HBV co-infection 
as determined using HBsAg testing.14,15 More up to 
date and comprehensive information about HBV 
co-infection in PLHIV who are taking ART is needed. 
The 2016 national ART guidelines, which are in line 
with WHO guidelines, recommend TDF + 3TC as the 
NRTI backbone in PLHIV starting ART for the first 
time (Table 1).16,17 This regimen is ideal for those also 
infected with HBV. However, sometimes adults and 
adolescents are started on a zidovudine (ZDV) + 3TC 
backbone and children may be given abacavir (ABC) 
instead of TDF (Table 1). In the routine setting, the 
National AIDS Programme is interested to know the 
proportion of PLHIV given TDF + 3TC and which 
NRTI backbone is being used among the remainder.
We therefore aimed to document the prevalence 
and associated risk factors of HBV co-infection among 
PLHIV starting first-line ART, as well as the NRTI back-
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Setting: There is little information about the diagnosis 
and treatment of hepatitis B virus (HBV) infection in peo-
ple living with HIV (PLHIV) in Zimbabwe despite recom-
mendations that tenofovir (TDF) + lamivudine (3TC) is 
the most effective nucleoside/nucleotide reverse tran-
scriptase inhibitor (NRTI) backbone of antiretroviral ther-
apy (ART) in those with dual infection.
Objective: To determine 1) numbers screened for hepa-
titis B surface antigen (HBsAg); 2) numbers diagnosed 
HBsAg-positive along with baseline characteristics; and 3) 
NRTI backbones used among PLHIV initiating first-line 
ART at Mpilo Opportunistic Infections Clinic, Bulawayo, 
Zimbabwe, between October 2017 and April 2019.
Design: This was a cross-sectional study using routinely 
collected data.
Results: Of the 422 PLHIV initiating first-line ART (me-
dian age 34 years, IQR 25–43), 361 (85%) were screened 
for HBV, with 10% being HBsAg-positive. HBsAg positivity 
was significantly associated with anaemia (adjusted prev-
alence ratio [aPR] 2.3, 95%CI 1.1–4.7) and elevated ala-
nine transaminase levels (aPR 2.9, 95%CI 1.5–5.8). Of 38 
PLHIV who were diagnosed HBsAg-positive, 30 (79%) 
were started on ART based on tenofovir (TDF) and lami-
vudine (3TC), seven were given abacavir (ABC) + 3TC-
based ART and one was given zido vudine (ZDV) + 3TC-
based ART.
Conclusion: In PLHIV, HBV screening worked well, the 
prevalence of HIV-HBV co-infection was high and most 
patients received appropriate treatment for both condi-
tions. Recommendations to improve screening, diagnosis 
and treatment of HIV-HBV co-infection are discussed.
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bones used in the ART regimens. Specific objectives 
were to determine 1) numbers screened for HBsAg; 2) 
numbers diagnosed HBsAg-positive, along with base-
line demographic and clinical characteristics; and 3) 
the NRTI backbone used in the first-line ART regimen 
among PLHIV initiating first-line treatment at the 
Mpilo Opportunistic Infections (OI) Clinic, Bulawayo, 
Zimbabwe, between October 2017 and April 2019.
METHOD
Study design
This was a cross-sectional study using secondary data.
Setting
General setting
Zimbabwe is a low-income country in southern Africa 
with a population of about 13 million and a gross do-
mestic product per capita of US$924.18,19 HIV remains 
a major health challenge, with an estimated 1.3 mil-
lion PLHIV at the end of 2016.13 By 2017, about one 
million out of the 1.3 million PLHIV had access to 
ART, up from just 12 000 in 2005.13 The country is 
making good progress towards the attainment of the 
UNAIDS 90-90-90 targets, with 74% of PLHIV know-
ing their HIV status, 87% of those diagnosed with 
HIV on ART and 87% of those on ART being virally 
suppressed.13
Specific setting and management of HIV and ART
Mpilo OI Clinic in Bulawayo was a pioneering and re-
ferral centre of excellence in ART roll-out in the public 
sector in Zimbabwe in 2004. With 11 500 PLHIV regis-
tered clients by the end of 2018, the centre is consid-
ered a high-volume ART facility. All PLHIV initiated on 
ART are registered in the ART register. An electronic 
patient record file has also been opened using national 
‘ePOC’ software, which serves as the primary data 
source and is updated at every patient visit. After start-
ing first-line ART, PLHIV are seen initially monthly 
and then 3-monthly for follow-up visits.
HBV screening in PLHIV and subsequent 
management at Mpilo Clinic
HBV screening at Mpilo OI commenced in October 
2017. All PLHIV newly initiating first-line ART are pri-
oritised and HBV screening is done within 1 month of 
initiating treatment. Whole blood is collected and 
screened for HBsAg (OnSite HBsAg Rapid test, CTK Bio-
tech Inc, CA, USA) at the laboratory located within the 
OI clinic. The results are entered into the paper-based 
laboratory register and the laboratory request form. 
The latter goes to the data clerk for entry into the 
ePOC file. For patients diagnosed with HIV-HBV coin-
fection, an abdominal ultrasound is carried out after 
the diagnosis has been made and a full set of liver 
function tests are performed every 3 months. If any of 
these tests are abnormal, the patients are referred to 
medical specialists for further management.
Study population
The study population included all PLHIV aged 5 
years who initiated first-line ART at Mpilo OI Clinic 
between October 2017 and April 2019. PLHIV who 
were referred or transferred in from another HIV clinic 
were excluded.
Data variables, source of data and data 
collection
Data variables included patient ID Number, whether 
screened for HBV infection (yes/no), HBsAg result 
(positive/negative), ART regimen used, age, sex, mari-
tal status, employment, height, weight, CD4 cell 
count, creatinine clearance (ml/min), haemoglobin 
(g/dl) and alanine transaminase level (ALT in U/L). 
Males with haemoglobin 13 g/dl and females with 
haemoglobin 12 g/dl were classified as anaemic.20 
Body mass index (BMI) was calculated in kg/m2. The 
data source for the study variables was the ‘ePOC’ 
database.
Analysis and statistics
Anonymised data were exported to MS Excel (Micro-
Soft, Redmond, WA, USA) for cleaning and format-
ting. After cleaning, the database was imported into 
EpiData Analysis 3.1 (EpiData Association, Odense, 
Denmark) and Stata v12 (StataCorp, College Station, 
TX, USA) for analysis. Categorical variables were 
summarised using frequencies and proportions; con-
tinuous variables were summarised using means and 
standard deviations or medians and interquartile 
ranges (IQRs). Key outcome variables were HBV 
screening and HBV co-infection. Factors associated 
with HBV co-infection were analysed using the χ2 
test and presented as prevalence ratios (PR) with 
95% confidence intervals (CIs). Modified Poisson re-
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TABLE 1 First-line ART regimens used in Mpilo Clinic, Bulawayo, Zimbabwe
Adults and adolescents Children
Preferred first-line  
ART




Alternative first-line  
ART






Adults, pregnant and 
breastfeeding women
2 weeks to 3 years ABC+3TC+LPV/r ZDV+ 3TC+ LPV/r
ABC+ 3TC+NVP
TB-HIV; HBV-HIV 3 years to 10 years ABC+3TC+EFV ZDV+3TC+EFV
ZDV+3TC+NVP
TDF+3TC+EFV (NVP) 
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gression was used with robust variance estimates to calculate 
adjusted prevalence ratios (aPRs) and 95% CIs. Levels of signifi-
cance were set at 5%.
Ethics
Permission for the study was obtained from the Mpilo Institu-
tional Ethics Review Board, Bulawayo, Zimbabwe. Ethics approval 
was obtained from the Medical Research Council of Zimbabwe, 
Harare, Zimbabwe (MRCZ/E/253); and the International Union 
Against Tuberculosis and Lung Disease Ethics Advisory Group, 
Paris, France (no 41/19). As the study involved only records re-
view, requirement for informed consent was waived.
RESULTS
Of the 422 PLHIV (median age 34 years, IQR 25–43) who initiated 
first-line ART, 361 (85.5%) were screened for HBV infection (Table 
2). Demographic and clinical characteristics were similar between 
those screened and not screened (data not shown). The propor-
tions screened for HBV were highest in the youngest age groups 
and declined in the older age groups, but there were no other dif-
ferences with respect to other baseline characteristics.
The proportion of PLHIV who were HBsAg-positive among 
those screened was 10.5% (95%CI 7.8–14.1). Baseline characteris-
tics associated with being HBsAg-positive are shown in Table 3. 
TABLE 2 Characteristics of PLHIV who were initiated on first-line ART and screened for hepatitis B in Mpilo Clinic, Bulawayo, Zimbabwe, 
2017–2019
Characteristics
Initiated first-line ART Screened for HBV
P valuen n (%)
 Total 422 361 (85.5)
Age group, years
 5–14 35 33 (94.3) 0.01
 15–24 69 62 (89.9)
 25–49 269 228 (84.8)
 50 49 38 (77.6)
Sex
 Male 181 152 (84.0) 0.43
 Female 241 209 (86.7)
Marital status
 Single 129 116 (89.9) 0.21
 Married 211 182 (86.3)
 Divorced/separated 49 41 (83.7)
 Widowed 20 17 (85.0)
 Missing data* 13 5 (38.5)
Employment status
 Unemployed 194 165 (85.1) 0.15
 Employed 155 135 (87.1)
 Student 59 55 (93.2)
 Missing data* 14 6 (42.9)
Body mass index, kg/m2
 18.5 93 84 (90.3) 0.32
 18.5–24.99 218 183 (83.9)
 25–29.99 72 61 (84.7)
 30 39 33 (84.6)
CD4 cell count/mm3
 200 110 96 (87.3) 0.58
 200 261 233 (89.3)
 Missing data* 51 32 (62.7)
Creatinine clearance, ml/min
 60 40 33 (82.5) 0.15
 60 356 320 (89.9)
 Missing data* 26 8 (30.8)
Anaemia
 Yes 165 144 (87.3) 0.41
 No 219 197 (90.0)
 Missing data* 38 20 (52.6)
Alanine transaminase level, U/L
 32 278 249 (89.6) 0.11
 >32 99 94 (94.9)
 Missing data* 45 18 (40.0)
* Not included in analysis.
PLHIV = people living with HIV; ART = antiretroviral therapy; HBV = hepatitis B virus.
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PR (95%CI) aPR (95%CI) P valuen n (%)
Total 361 38 (10.5)
Age group, years 361 38
 5–14 33 2 (6.1) 0.5 (0.1–2.0) 0.7 (0.1–5.5) 0.73
 15–24 62 5 (8.1) 0.7 (0.3–1.6) 0.6 (0.2–1.8) 0.33
 25–49 228 28 (12.3) Reference
 50 38 3 (7.9) 0.6 (0.2–2.0) 0.7 (0.2–2.3) 0.51
Sex 361 38
 Male 152 19 (12.5) Reference
 Female 209 19 (9.1) 0.7 (0.4–1.3) 0.8 (0.4–1.5) 0.44
Marital status 356 38
 Single 116 14 (12.1) 1.3 (0.7–2.5) 1.5 (0.6–3.5) 0.40
 Married 182 17 (9.3) Reference
 Divorced/separated 41 7 (17.1) 1.8 (0.8–4.1) 1.5 (0.6–3.7) 0.42
 Widowed 17 0 (0.0) –
Employment 355* 38
 Unemployed 165 21 (12.7) Reference
 Employed 135 12 (8.9) 0.7 (0.4–1.4) 0.78 (0.4–1.7) 0.54
 Student 55 5 (9.1) 0.7 (0.3–1.8) 1.35 (0.3–5.6) 0.42
Body mass index, kg/m2 361 38
 18.5 84 10 (11.9) 1.1 (0.5–2.2) 1.1 (0.5–2.6) 0.86
 18.5–24.99 183 20 (10.1) Reference
 25–29.99 61 7 (11.5) 1.1 (0.5–2.4) 1.4 (0.6–3.5) 0.50
 30 33 1 (3.0) 0.3 (0.1–2.0) 0.5 (0.1–4.0) 0.51
CD4 cell count/mm3 329* 38
 200 96 17 (17.7) 2.0 (1.1–3.6) 1.38 (0.7–2.7) 0.35
 200 233 21 (9.0) Reference
Creatinine clearance, ml/min 353* 37
 60 33 5 (15.2) 1.5 (0.6–3.6) 0.91 (0.3–2.6) 0.86
 60 320 32 (10.0) Reference
Anaemia 341* 37
 Yes 144 25 (17.4) 2.8 (1.4–5.4) 2.3 (1.1–4.7) 0.03
 No 197 12 (6.1) Reference
Alanine transaminase level, U/L 343* 38
 >32 94 23 (24.5) 4.1 (2.2–7.4) 2.9 (1.5–5.8) 0.002
 32 249 15 (6.0) Reference
* Missing data not included in analysis. All variables included in the adjusted model.
HBV = hepatitis B virus; PLHIV = people living with HIV; HBsAg = hepatitis B surface antigen; PR = prevalence ratio; CI = confidence interval; aPR = adjusted PR.
TABLE 4 Treatment regimens of PLHIV who were initiated on first-line ART in Mpilo Clinic, Bulawayo, Zimbabwe, in relation to being 
screened for and diagnosed with HBV, 2017–2019
Nucleoside/nucleotide reverse transcriptase 
inhibitor backbone of first-line ART
Total PLHIV Screened for HBV Diagnosed HBsAg-positive
n n (%)* n (%)*
All ART regimens 422 361 38
Initiated on TDF+3TC backbone 378 324 (89.8) 30 (78.9)
Initiated on 3TC backbone only 44 37 (10.2) 8 (21.1)
Initiated on neither TDF or 3TC backbone 0 0 (0) 0 (0)
* Column percentages.
PLHIV = people living with HIV; ART = antiretroviral therapy; HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; TDF = tenofovir; 3TC = lamivudine.
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Being anaemic (aPR 2.3, 95%CI 1.1–4.7) and having a raised se-
rum ALT (aPR 2.9, 95%CI 1.5–5.8) at baseline were significantly 
associated with being HBsAg-positive.
The NRTI backbones used in first-line treatment in relation to 
HBV screening and being diagnosed HBsAg-positive are shown in 
Table 4. A TDF + 3TC-based regimen was used in 378 (90%) PLHIV 
initiating first-line ART. Of the 44 PLHIV not initiated on a TDF + 
3TC-based regimen, 37 (84.1%) were screened for HBV and 8 were 
diagnosed HBsAg-positive. ART regimens that did not include 
TDF + 3TC were given to eight PLHIV who were HBsAg-positive 
(Table 5). Altogether, 7 PLHIV were given ABC + 3TC backbones: 
in 4 this was because of renal impairment (based on the estimated 
glomerular filtration rate) and TDF was therefore contraindicated, 
and in the other 3 PLHIV the reasons were unknown. One PLHIV 
was given ZDV + 3TC, the stated reason being an inappropriate 
weight for TDF. The four patients in whom TDF was not contrain-
dicated were traced and placed on a TDF-based regimen.
DISCUSSION
This is the first study in the past 5 years in Zimbabwe to docu-
ment the prevalence of HBV co-infection among PLHIV who ini-
tiated ART for the first time, as well as the ART regimens that were 
being used. There were some interesting findings.
Under routine programmatic conditions, there were high rates 
of HBV screening. The only baseline characteristic that showed 
any association with screening was age, with a high proportion of 
children screened and rates tailing off in those aged 50 years. 
The proportion of those screened who were HBsAg-positive was 
about 10%, with the highest proportions found in those with 
anaemia and with elevated serum transaminases levels. It was re-
assuring to observe that four fifths of those with HIV-HBV co-in-
fection were receiving appropriate treatment with a TDF + 3TC 
NRTI backbone, while the remainder received partial HBV treat-
ment with a 3TC backbone alone.
The high HBV screening rate may be attributed to the integra-
tion of HBV screening with HIV care. Screening was also en-
hanced by the availability of an onsite laboratory and funding 
through partnership with a non-governmental organisation. The 
observed HIV-HBV prevalence was comparable with results from 
Zimbabwe in 2014,15 and from other African countries such as 
Mozambique and Lesotho,8,21 but was higher than the prevalence 
reported from Ghana, Ethiopia and South Africa.10,11,22 An earlier 
study in Zimbabwe with samples collected in 2003–2009 showed 
a higher HIV-HBV prevalence of 17%.14 The explanation might be 
that this was an older population that did not benefit from the 
national hepatitis B vaccination programme which started in 
1999.23
In our study, sociodemographic factors were not associated 
with HBV infection; this is in line with findings in Ghana and 
Tanzania.10,24 Several studies have reported an association be-
tween raised serum ALT at baseline and HBV-HIV co-infec-
tion.21,25–27 This is in line with our findings, and is not surprising 
as HIV infection promotes both HBV replication and reactivation, 
leading to a more aggressive natural history of HBV and chronic 
hepatitis B, which is associated with elevated transaminase lev-
els.12 While some studies have observed an association between 
HBV co-infection, male sex and low CD4 cell counts (200 cells/
mm3),9,11,15,28 we did not find any such an association. Instead, 
anaemia was associated with HBV co-infection in patients initiat-
ing first-line ART. Anaemia is associated with advanced HIV dis-
ease and severe immunosuppression,29,30 and it is this factor that 
most probably explains the associated link with HBV.
We could not identify any previous studies from Africa specifi-
cally on the drugs used to treat HIV-HBV co-infection. It was reas-
suring to observe that most PLHIV received the appropriate TDF + 
3TC NRTI backbone, in line with guidelines. Renal impairment 
was responsible for approximately half of PLHIV just receiving the 
3TC backbone (TDF being contraindicated in these circumstances). 
Why the remainder was not given TDF is unclear, and more infor-
mation is needed in future about these treatment selections.
There were several strengths to the study. It was conducted 
within the routine programme setting and results therefore mimic 
current practice. Selection bias was minimised by enrolling consecu-
tive PLHIV within the study period. However, there were some lim-
itations. Our results may not be generalisable to the rest of the coun-
try owing to the uniqueness of the study setting. Indeed, significant 
gaps with regards to national hepatitis B diagnosis and treatment 
were noted during the 2017 rapid assessment on viral hepatitis.31 
We were not able to conduct the whole spectrum of HBV serological 
tests to further characterise the infection; as these were not avail-
able, we were unable to assess the degree of liver disease associated 
with being HBsAg-positive, we collected no information about hep-
atitis B vaccination and HIV viral load was not measured at each 
follow-up visit. We excluded children aged 5 years because of diffi-
culties in calculating parameters such as BMI and CD4 cell counts 
and because data in this group were often incomplete.
Despite these limitations, our study has three practical pro-
grammatic implications. First, there is need for formal linkage to 
care of PLHIV diagnosed with HBV infection to ensure they are all 
initiated on a TDF + 3TC NRTI backbone whenever possible. Sec-
ond, since management of HBV co-infection with 3TC monother-
apy may lead to viral resistance and fatal flare-ups of viral hepati-
tis, there is need for the National AIDS Programme to avail 
alternative regimens when TDF is contraindicated. Already there 
are alternative drugs that can be used for both HIV and HBV.32 For 
example, tenofovir alafenamide (TAF) has a much better safety 
profile with respect to renal adverse events and is effective in pa-
tients with 3TC-resistant HBV.2,32,33 TAF is now available in Zim-
babwe. Finally, if resources are scarce, targeted HBV screening for 
PLHIV with anaemia and elevated ALT could be considered. HIV-
HBV coinfection in Zimbabwe needs more attention. Two recent 





years Reason for ART regimen
ABC+3TC+EFV 6 14, 23, 30, 43, 50, 61 Four had renal impairment and TDF contraindicated
Two had unknown reasons
ABC+3TC+LPV/r 1 36 Unknown reason
ZDV+3TC+EFV 1 12 Low body weight below TDF weight threshold of 30 kg
ART = antiretroviral therapy; TDF = tenofovir; 3TC = lamivudine; PLHIV = people living with HIV; HBsAg = hepatitis B surface antigen; ABC = abacavir; EFV = efavirenz; LPV/r = 
lopinavir/ ritonavir; ZDV = zidovudine.
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African studies have shown a high mortality in PLHIV with HBV 
coinfection despite ART.34,35 Further research is needed to assess 
what interventions are needed to prevent these deaths.
In conclusion, routine HBV screening performed well, and 
10% were diagnosed HbsAg-positive in PLHIV who initiated first-
line ART at Mpilo OI Clinic, Bulawayo, Zimbabwe. The majority 
of PLHIV with HBV co-infection received appropriate treatment 
with a TDF + 3TC NRTI backbone, with the remainder being 
treated with a 3TC-only backbone. Practical recommendations are 
made to improve the screening, diagnosis and management of 
PLHIV with HBV co-infection.
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Contexte  :  Il existe peu d’informations relatives au diagnostic et au 
traitement de l’hépatite B (HBV) chez les personnes vivant avec le VIH 
(PLHIV) au Zimbabwe en dépit des recommandations selon lesquelles 
l’association tenofovir (TDF) + lamivudine (3TC) est le plus efficace 
inhibiteur nucléoside/nucléotide de la transcriptase inverse (NRTI), 
pierre angulaire du traitement antirétroviral (TAR) des patients 
atteints des deux infections.
Objectif  :  Déterminer 1) le nombre de personnes dépistées pour 
l’antigène HBs (HBsAg); 2) le nombre de personnes diagnostiquées 
comme positives à l’HBsAg ainsi que leurs caractéristiques de départ ; 
et 3) les NRTI principales utilisées parmi les PLHIV initiant un TAR de 
première ligne au service des infections opportunistes de Mpilo 
Hospital, à Bulawayo, Zimbabwe, entre octobre 2017 et avril 2019.
Schéma  :  Ceci est étude transversale basée sur des données recueillies 
en routine.
Résultats  :  Il y a eu 422 PLHIV initiant un TAR de première ligne. Leur 
âge médian a été de 34 ans (IQR 25–43). Parmi eux, 361 (85%) ont 
eu un dépistage du HBV dont 10% ont été HBsAg-positifs. La 
positivité du HbsAg a été significativement associée avec une anémie 
(taux de prévalence ajusté [PRa] 2,3 ; IC95% 1,1–4,7) et avec une 
élévation des taux d’alanine transaminase (PRa 2,9 ; IC95%, 1,5–5,8). 
Sur 38 PLHIV diagnostiqués HBsAg-positifs, 30 (79%) ont été mis 
sous TAR basé sur du TDF + 3TC, 7 ont reçu un TAR basé sur abacavir 
+ 3TC et 1 patient a reçu un TAR basé sur zidovudine + 3TC.
Conclusion  :  Chez les PLHIV, le dépistage du HBV a bien fonctionné, 
la prévalence de la coinfection à VIH-HBV a été élevée et la majorité 
des patients a reçu un traitement approprié pour les deux 
pathologies. Les recommandations visant à améliorer le dépistage, 
le diagnostic et le traitement de la coinfection VIH et HBV sont 
discutées.
Marco de Referencia: Existe poca información sobre el diagnóstico 
y el tratamiento de la infección por el virus de la hepatitis B (HBV) en 
personas con infección por el VIH (PLHIV) en Zimbabwe, pese a la 
recomendación de tratar con tenofovir (TDF) + lamivudina (3TC), un 
tratamiento antirretrovírico (TAR) con una base de análogos 
nucleosídico y nucleotídico inhibidores de la retrotranscriptasa 
(NRTI), que es el tratamiento más eficaz en las personas con esta 
infección doble.
Objetivo: Determinar 1) el número de pacientes con detección 
sistemática del antígeno de superficie de la hepatitis B (HBsAg); 2) el 
número de casos con un resultado positivo para el HBsAg y sus 
características iniciales; y 3) el tipo de tratamiento utilizado a base de 
NRTI en las PLHIV que iniciaron un TAR de primera línea en el 
consultorio de infecciones oportunistas del hospital Mpilo de 
Bulawayo, en Zimbabwe, de octubre del 2017 a abril del 2019.
Método: Fue este un estudio transversal a partir de los datos 
recogidos sistemáticamente.
Resultados: Se presentaron 422 personas con infección por el VIH 
que iniciaron TAR de primera línea. La mediana de la edad fue 34 
años (IQR 25–43). En 361 de estas personas (85%) se realizó la 
detección de la HBV y 10% tuvo un resultado positivo para el HBsAg. 
Este resultado positivo se asoció de manera significativa con anemia 
(tasa de prevalencia ajustada [aPR] 2,3; IC95% 1,1–4,7) y 
concentraciones altas de alanina-aminotransferasa (aPR 2,9; IC95% 
1,5–5,8). De los 38 pacientes con infección por el VIH y diagnóstico 
positivo para HBsAg, 30 (79%) iniciaron un TAR a base de TDF + 3TC, 
en 7 el TAR consistió en abacavir + 3TC y 1 paciente recibió 
zidovudina + 3TC.
Conclusión: La detección sistemática de la HBV en las personas con 
infección por el VIH tuvo un buen rendimiento; la prevalencia de 
coinfección fue alta y la mayoría de los pacientes recibió un 
tratamiento apropiado para ambas afecciones. Se analizan 
recomendaciones que pueden mejorar la detección sistemática, el 
diagnóstico y el tratamiento de la coinfección por el VIH y el HBV.
